NEWS
January 3, 2012 | By Amina Khan, Los Angeles Times / For the Booster Shots blog
Local Chinese health officials have appealed for calm after the death of a man infected with H5N1 bird flu in the city of Shenzhen. "Though it is highly pathogenic to human beings, the virus can not spread among people," said in a statement from the Shenzhen Center for Disease Control and Prevention. "There is no need for Shenzhen citizens to panic. " The man, a 39-year-old bus driver, developed a fever on Dec. 21 and was hospitalized Dec. 25. He died a week after two diseased dead birds were identified in nearby Hong Kong.
NEWS
September 5, 2011 | By Eryn Brown, Los Angeles Times / for the Booster Shots blog
The American Academy of Pediatrics released updated flu vaccine recommendations last week. Even though this season's vaccine protects against the same three strains of influenza as last year's -- Influenza A (H3N2), Influenza A (H1N1) and Influenza B -- parents are advised to vaccinate their children again this year. That's because the vaccine only offers optimal protection for six to 12 months, according to the AAP. This season is just the fourth time in a quarter of a century that the vaccine has stayed the same for a second year.
BUSINESS
June 2, 2011 | By Stuart Pfeifer, Los Angeles Times
A Redondo Beach man who invented the cold treatment gel Zicam was arrested on federal charges of illegally marketing another drug during a 2005 worldwide bird flu scare. Charles B. Hensley was arrested on charges that he sold the drug Vira 38 as a "prevention and treatment" of influenza and bird flu without Food and Drug Administration approval, said Assistant U.S. Atty. Pio Kim. Hensley was taken into custody at his home on Wednesday and held overnight at the Metropolitan Detention Center.
CALIFORNIA | LOCAL
March 4, 2011 | By Thomas H. Maugh II, Los Angeles Times
Dr. Edwin D. Kilbourne, a virologist who figured out how to manufacture a new influenza vaccine each year and was a principal advisor to the U.S. government on flu, died Feb. 21 in Branford, Conn. He was 90. No cause of death was released. Kilbourne was involved in every aspect of preparing vaccines for the influenza season, understanding the genetics of the virus, manipulating it to create a version that would grow in eggs, and helping make the recommendation of what the vaccine formulation should be each year, Food and Drug Administration officials said on his formal retirement in 2002.
NEWS
February 16, 2011 | By Thomas H. Maugh II, Los Angeles Times
A new influenza vaccine grown in cultured animal cells rather than eggs is at least as effective as conventional vaccines, a finding that could speed approval of the new way of producing the vaccine, researchers reported Tuesday. If the manufacturing technique is approved, it could improve the ability of vaccine makers to respond to emerging viruses and pandemics. The vaccine for the recent H1N1 influenza pandemic, for example, did not become available until the outbreak had already crested.
NEWS
January 11, 2011 | By Melissa Healy, Los Angeles Times
It was thrown together in a hurry, only aimed to protect against one strain of influenza, and arrived on the market well after the novel flu virus had gained a foothold in the general population. But last year's vaccine against the novel H1N1 flu, in the final analysis, worked pretty well, according to a European study published Tuesday in the journal Public Library of Science (PLoS) One . The study, which tested the effectiveness of the H1N1 flu vaccine at surveillance sites scattered across Europe, found that a single dose of H1N1 flu vaccine, which was offered as a shot and in mist form, was 71.9% effective in protecting against infection with the H1N1 virus.